Journal of Clinical Oncology
Articles in this Issue
Clinical characteristics and risk factors of individuals ineligible for lung cancer screening at a tertiary care center.
10529 Background: Lung cancer screening (LCS) reduces mortality, yet many individuals with lung cancer do not meet the 202...
Evaluation of factors affecting diagnostic delay in patients referred to the pediatric oncology clinic of Ankara University: A developing country model.
e22010 Background: Early diagnosis is a major determinant of survival and treatment success in childhood cancers. However,...
Patterns, causes, and predictors of inpatient mortality among cancer patients in a tertiary center in south India: A 10-year retrospective analysis.
e24049 Background: Inpatient mortality among cancer patients reflects a complex interaction between advanced disease, trea...
OP-NEU-101: A phase 1/2 open-label, dose finding and expansion study to investigate the safety and effectiveness and determine the optimal dose of N17350 administered intratumorally in participants with advanced solid tumors.
TPS2679 Background: Despite advances in targeted therapies and immunotherapy, many patients with advanced solid tumors hav...
Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.
5005 Background: Androgen receptor pathway inhibitors (ARPIs) may have distinct central nervous system (CNS) penetration a...
PROTRACT: A randomized phase II trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician’s choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).
5017 Background: A subset of mCRPC patients (pts) will benefit from enzalutamide (ENZA) following disease progression on A...
Mental health and malignancy: Real-world associations between early-onset gastrointestinal cancers and mental illness.
11174 Background: Although progress has been made in reducing overall cancer incidence, early-onset cancers have continued...
Sun-protective behaviours amongst indigenous communities: A scoping review.
e21583 Background: Due to longstanding historical and systemic barriers, Indigenous communities experience disproportionat...
Outcomes of gastrointestinal malignancies in HIV: The impact of opportunistic and non-opportunistic infections.
e16350 Background: Gastrointestinal (GI) malignancies are a major source of cancer-related mortality. Human immunodeficien...
Pretreatment spatial immune architecture and 1-year clinical benefit to first-line ICB in advanced melanoma.
9539 Background: Predictive biomarkers for immune checkpoint blockade (ICB) in advanced cutaneous melanoma (CM) remain lim...
Neoadjuvant intravenous biosimilar pertuzumab and trastuzumab versus subcutaneous pertuzumab/trastuzumab/hyaluronidase (Phesgo) in HER2-positive breast cancer: A real-world comparative study.
e12604 Background: Dual HER2 blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuva...
The effect of automated quantitative evaluation of lesion response heterogeneity in patients with metastatic neuroendocrine tumors.
e16318 Background: Neuroendocrine tumors (NET) are a biologically diverse set of neoplasms that vary in malignant potentia...
A systems-level omics and hallmark–based analysis of pancreatic cancer for the identification of potential multi-target drugs.
e16441 Background: Pancreatic cancer is a highly aggressive malignancy with limited therapeutic options. Advances in omics...
Omitting postoperative radiotherapy after pathologic complete response to neoadjuvant immunochemotherapy for patients with locally advanced head and neck squamous cell carcinoma: Survival and patient-reported outcomes.
6105 Background: Neoadjuvant immunochemotherapy (NICT) results in high pathologic response rates in locally advanced head...
Prevention of paclitaxel-induced peripheral neuropathy using limb cryotherapy: Evidence from a resource-constrained setting.
e12690 Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a common, dose-limiting toxicity that significantly...
An observational study to investigate the effectiveness and safety of niraparib maintenance therapy after frontline chemotherapy for Taiwanese patients with advanced ovarian cancer: Interim results.
e17546 Background: The phase 3 PRIMA trial demonstrated that first-line maintenance therapy (1LMT) with niraparib signific...
Clinical and translational study of p38 inhibitor pexmetinib plus nivolumab following anti–PD-1/L1 failure in advanced solid tumors.
2515 Background: Cancers resistant to immune checkpoint blockade typically harbor a non-T cell-inflamed phenotype, charact...
Safety and efficacy of immunotherapy rechallenge in solid tumors after discontinuation of immune checkpoint inhibitors for immune-related adverse events: A systematic review and meta-analysis.
11127 Background: Immune-related adverse events (irAEs) often require treatment discontinuation in patients with cancer re...
Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4–targeting ADC) from pharmacokinetics, efficacy, and safety perspectives.
3029 Background: B7-H4 is a transmembrane glycoprotein that is upregulated in a variety of solid tumors. BG-C9074 is an in...
Molecular characteristics of therapy-related myeloid neoplasms in PARP inhibitor–treated patients.
6597 Background: Poly ADP-ribose polymerase inhibitors (PARPi) are part of standard therapy in solid tumors, and is associ...
Molecular profiling of male breast cancer in Brazil: Comprehensive genomic characterization of a Latin American cohort.
571 Background: Male breast cancer (MBC) is a rare disease, accounting for < 1% of all breast cancers. Current treatmen...
A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).
5575 Background: Patients with platinum-resistant ovarian cancer (PROC) have few therapeutic options. More than 60% of hig...
The obesity paradox in colon cancer hospitalizations: Mortality and cardiovascular risk.
e15716 Background: Obesity is a well-established risk factor for colorectal cancer (CRC) and is associated with adverse on...
Time-resolved cardiovascular risk after immune checkpoint inhibitors: A large real-world cancer cohort study.
12023 Background: With expanding use of immune checkpoint inhibitors (ICIs), immune-related toxicities increasingly influe...
Factors influencing the selection of CheckMate-9LA (nivolumab, ipilimumab, and chemotherapy) regimen in AGA-negative advanced NSCLC.
e20667 Background: The treatment of advanced non-small cell lung cancer (aNSCLC) without actionable genomic alteration (AG...